Roivant Sciences Fast-Tracks Key Drug Development Programs

MT Newswires Live12-11

Roivant Sciences (ROIV) said Thursday it has fast-tracked four of its key drug development programs.

The new drug application filing for Brepocitinib in dermatomyositis is now expected early next year, with a commercial launch expected in early 2027. The company said its phase 3 trial for the drug candidate in non-infectious uveitis is fully enrolled, with topline data now expected in H2 2026.

Meanwhile, the Brepocitinib proof-of-concept trial in cutaneous sarcoidosis is fully enrolled, with topline data expected in H1 2026.

For the IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis, topline data are now expected next year, the company said.

Roivant also said it led a funding round for Immunovant (IMVT) that garnered gross proceeds of around $550 million. The funding will extend Immunovant's cash runway to the launch of IMVT-1402 in Graves' disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590511175?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 22:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590511175","market":"sg","top_or_hot":-1,"title":"Roivant Sciences Fast-Tracks Key Drug Development Programs","media":"MT Newswires Live","content":"<html><body><p> Roivant Sciences (ROIV) said Thursday it has fast-tracked four of its key drug development programs.</p><p>The new drug application filing for Brepocitinib in dermatomyositis is now expected early next year, with a commercial launch expected in early 2027. The company said its phase 3 trial for the drug candidate in non-infectious uveitis is fully enrolled, with topline data now expected in H2 2026.</p><p>Meanwhile, the Brepocitinib proof-of-concept trial in cutaneous sarcoidosis is fully enrolled, with topline data expected in H1 2026.</p><p>For the IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis, topline data are now expected next year, the company said.</p><p>Roivant also said it led a funding round for Immunovant (IMVT) that garnered gross proceeds of around $550 million. The funding will extend Immunovant's cash runway to the launch of IMVT-1402 in Graves' disease.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roivant Sciences Fast-Tracks Key Drug Development Programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoivant Sciences Fast-Tracks Key Drug Development Programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-11 22:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Roivant Sciences (ROIV) said Thursday it has fast-tracked four of its key drug development programs.</p><p>The new drug application filing for Brepocitinib in dermatomyositis is now expected early next year, with a commercial launch expected in early 2027. The company said its phase 3 trial for the drug candidate in non-infectious uveitis is fully enrolled, with topline data now expected in H2 2026.</p><p>Meanwhile, the Brepocitinib proof-of-concept trial in cutaneous sarcoidosis is fully enrolled, with topline data expected in H1 2026.</p><p>For the IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis, topline data are now expected next year, the company said.</p><p>Roivant also said it led a funding round for Immunovant (IMVT) that garnered gross proceeds of around $550 million. The funding will extend Immunovant's cash runway to the launch of IMVT-1402 in Graves' disease.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMVT","symbol_name":"Immunovant, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590511175","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590511175","pubTimestamp":1765462310,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Roivant Sciences  said Thursday it has fast-tracked four of its key drug development programs.The new drug application filing for Brepocitinib in dermatomyositis is now expected early next year, with a commercial launch expected in early 2027. The company said its phase 3 trial for the drug candidate in non-infectious uveitis is fully enrolled, with topline data now expected in H2 2026.Meanwhile, the Brepocitinib proof-of-concept trial in cutaneous sarcoidosis is fully enrolled, with topline data expected in H1 2026.For the IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis, topline data are now expected next year, the company said.Roivant also said it led a funding round for Immunovant  that garnered gross proceeds of around $550 million. The funding will extend Immunovant's cash runway to the launch of IMVT-1402 in Graves' disease.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMVT":"Immunovant, Inc.","BK4588":"碎股","ROIV":"Roivant Sciences Ltd.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4007":"制药"},"translate_title":"Roivant Sciences快速推进关键药物开发项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":1,"IMVT":1},"content_text":"Roivant Sciences (ROIV) said Thursday it has fast-tracked four of its key drug development programs.The new drug application filing for Brepocitinib in dermatomyositis is now expected early next year, with a commercial launch expected in early 2027. The company said its phase 3 trial for the drug candidate in non-infectious uveitis is fully enrolled, with topline data now expected in H2 2026.Meanwhile, the Brepocitinib proof-of-concept trial in cutaneous sarcoidosis is fully enrolled, with topline data expected in H1 2026.For the IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis, topline data are now expected next year, the company said.Roivant also said it led a funding round for Immunovant (IMVT) that garnered gross proceeds of around $550 million. The funding will extend Immunovant's cash runway to the launch of IMVT-1402 in Graves' disease.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590511175","isCrawlerRequest":true}